Loading
The US oncology society's 2021 rules for treatment before surgery: triple-negative tumours of 1 cm or more, or with involved nodes, should get anthracycline and taxane chemotherapy, carboplatin may be added, and at that date the evidence for adding immunotherapy was judged insufficient.
ASCO guideline by Korde, Somerfield, Carey, Crews and colleagues, based on a systematic review of 41 articles. Patients on neoadjuvant therapy should be managed by a multidisciplinary team; candidates include inflammatory breast cancer and cases where residual disease would change therapy, and neoadjuvant treatment can reduce the extent of local therapy. Tumour histology, grade, stage and receptor status should guide decisions; other markers and genomic profiles lack evidence. Triple-negative patients with clinically node-positive or at least T1c disease should be offered an anthracycline- and taxane-containing regimen; cT1a or cT1bN0 disease should not routinely be offered neoadjuvant therapy; carboplatin may be offered to increase pathological complete response; evidence was insufficient to add immune checkpoint inhibitors. Hormone receptor-positive and HER2-positive recommendations are also given.
The last major guideline written before KEYNOTE-522 changed the standard; the 2022 rapid update reversed the immunotherapy line within a year.
Shares Taxanes (paclitaxel, docetaxel, nab-paclitaxel), Anthracyclines (doxorubicin, epirubicin), Neoadjuvant / adjuvant / perioperative, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Pathologic complete response (pCR), Neoadjuvant / adjuvant / perioperative, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Journal of Clinical Oncology and the tag tnbc-evidence.
Shares Pathologic complete response (pCR), Neoadjuvant / adjuvant / perioperative, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Journal of Clinical Oncology and the tag tnbc-evidence.
Shares American Society of Clinical Oncology (ASCO), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Journal of Clinical Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Pathologic complete response (pCR), Neoadjuvant / adjuvant / perioperative, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Journal of Clinical Oncology and the tag tnbc-evidence.
Shares American Society of Clinical Oncology (ASCO), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Journal of Clinical Oncology, Carboplatin and the tag tnbc-evidence.
Shares Pathologic complete response (pCR), Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Carboplatin, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Journal of Clinical Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.